Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Economic analysis alongside clinical trials. Bias in the assessment of economic outcomes.

Literature DB >> 9136476

Economic analysis alongside clinical trials. Bias in the assessment of economic outcomes.

L B Ellwein¹, M F Drummond.
1. University of York.

Abstract

Clinical trial randomization schemes to control patient characteristics that can influence clinical response are not sufficient to control for their effects on operational efficiency and cost within the provider institution. This variation can result in biased economic findings when patients are allowed to select a provider themselves.

Entities: Species

Mesh：

Year: 1996 PMID： 9136476 DOI： 10.1017/s0266462300010977

Source DB: PubMed Journal: Int J Technol Assess Health Care ISSN： 0266-4623 Impact factor: 2.188

Keyword Cloud
Cited

11 in total

Review 1. Design, analysis and presentation of multinational economic studies: the need for guidance.

Authors: Francis Pang
Journal: Pharmacoeconomics Date: 2002 Impact factor: 4.981

Review 2. Testing the validity of cost-effectiveness models.

Authors: C McCabe; S Dixon
Journal: Pharmacoeconomics Date: 2000-05 Impact factor: 4.981

3. Common errors and controversies in pharmacoeconomic analyses.

Authors: J Soto
Journal: Pharmacoeconomics Date: 1998-12 Impact factor: 4.981

4. Applying health technology assessment to pharmaceutical care: pitfalls and future directions.

Authors: Steven Simoens; Gert Laekeman
Journal: Pharm World Sci Date: 2005-04

Review 5. Patient self-reports in pharmacoeconomic studies. Their use and impact on study validity.

Authors: C Evans; B Crawford
Journal: Pharmacoeconomics Date: 1999-03 Impact factor: 4.981

6. Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis.

Authors: C A Estrada; C J Mansfield; G R Heudebert
Journal: J Gen Intern Med Date: 2000-02 Impact factor: 5.128

7. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

Authors: U Siebert; G Sroczynski; S Rossol; J Wasem; U Ravens-Sieberer; B M Kurth; M P Manns; J G McHutchison; J B Wong
Journal: Gut Date: 2003-03 Impact factor: 23.059